NormalhumanbronchialepithelialcellswithexcellentpackedcuboidalmorphologygrowninBEGM™BulletKit™(underlightmicroscopy)
ProductOverview
| Bronchialepithelialcells(NHBEandDHBE)areisolatedfromepithelialliningof airwaysabovebifurcationofthelungs. Lonza"sNormalHumanBronchialEpithelialCells(NHBE)areavailable withorwithout retinoicacid. NHBEslabeledCC-2540Saresuitableforair-liquidinterfacestudiesandareguaranteedfordifferentiationmarkedbyciliaformation,mucinproduction,andTEERlevels. | Interestedtolearnmore?
Requestinfoorquote |
DiseasedHumanBronchialEpithelialCells(DHBE)arealsoavailablefromdonorsdiagnosedwith asthma,COPDandcysticfibrosis.Detaileddonorinformationforthesecellscanbeobtainedbycontactingourscientificsupportteam.DHBEslabeled00195275Sand00194911Saresuitableforair-liquidinterfacestudiesandareguaranteedfordifferentiationmarkedbyciliaformation,mucinproduction,andTEERlevels.
AllCryopreservedhumanbronchialepithelialcellsareguaranteedthrough15populationdoublings.Cells testnegativeformycoplasma,bacteria,yeast,andfungi.HIV-1,hepatitisBandhepatitisCarenotdetectedforalldonorsand/orcelllots.ACertificateofAnalysisisprovidedforeachcelllotpurchased.
RecommendedMedium: BEGM™BulletKit™.
RecommendedSubculturingReagents: ReagentPack™SubcultureReagent
| WhitePapers | ||
Registertodownload |
|
SelectedApplications
Lonza"sPrimaryNHBECellsasImportantControlinSide-by-SideComparisonwithWell-establishedNormalLungEpithelialCellLines |
Furukawa,etal.demonstratesBEGM™BulletKit™ issuitableforculturingLonza"sNHBEsaswellastosupportco-cultureswithlungepithelialcellline,BEAS-2B,andbreastcancercelllines,MCF-7andMDA-MB-231.ThebreastcancercelllineshoweddifferencesinmorphologyandproliferationrateswhenculturedwithprimaryNHBEcellsvs.BEAS-2Bcellline.ThepaperhighlightstheimportanceofusingprimaryNHBEcellsasaside-by-sidecontrolwhenconductingexperimentswithnormallungepithelialcelllinesuchasBEAS-2Bbecausethenon-transformedprimarycellscanvalidateoroffsetthedatageneratedusingcelllines.
|
FurtherApplicationswithLonza’sHumanBronchialEpithelialCells
- “ARotatingBioreactorforScalableCultureandDifferentiationofRespiratoryEpithelium”.Respiratoryepitheliumisdifficulttogrowinvitro,asitrequiresawell-maintainedpolarizingair‐liquidinterface(ALI)tomaintaindifferentiation.Raredonetal.describeascalableandeasymethodtoconductair-liquidinterfacewithLonza’sbronchialepithelialcellsguaranteedforALIdifferentiation(Cat.No.CC-2540S).
- CellconcentrationandspaceforgrowtharerequiredforproductiveNHBEcellbranchinginvitro.ClicktoreadthisarticlebyHagiwaraet.althatshowshowco-cultureswithHUVECsin3Dcultureinfluencereconstructionofbranchedtubularstructuresinlungepithelialcells.
- Wu,etal.reportsforthefirsttimethatHBEcellswhengrowninB-ALIMediumcandifferentiateinto3Dglandularacinarstructures,likesalivaryandmammaryepithelial.ThecellsweregrownonthebasementmembranematrixMatrigelunder selectconditionsandhaveshowntoexhibitformationofbrochospheresortracheosphereswithciliatedlining.
New!PurchaseourBronchialEpithelialCellCultureKit(catalogno.CC-2540B)andgetadiscountedpriceoncellsandmedia.Thekitconsistsofacryopreservedampuleofbronchialepithelialcells(catalogno.CC-2540)andBEGM™BulletKit™GrowthMedia(catalogno.CC-3170)
龙沙生物技术有限公司于2019年05月10日成立。法定代表人David Johann Wach，公司经营范围包括：生物技术开发服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术推广服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术咨询、交流服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;生物技术转让服务（我国稀有和特有的珍贵优良品种，国家保护的原产于我国的野生动、植物资源开发除外）;医学研究和试验发展（人体干细胞、基因诊断与治疗技术除外）;药品研发（人体干细胞、基因诊断与治疗技术除外）;货物进出口(涉及外资准入特别管理规定和许可审批的商品除外);技术进出口;贸易代理;商品批发贸易（涉及外资准入特别管理规定和许可审批的商品除外）;生物药品制造;化学药品原料药制造;化学药品制剂制造等。
本网站将在规定时间内给予删除等相关处理。
